ECTRIMS 2023 | Concurrent malignant tumor near the onset of MOGAD

Young Nam Kwon, MD, Seoul National University, Seoul, South Korea, discusses a study investigating the incidence of concurrent cancer at the onset of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Data from two major cohorts – one from Korea and another from the Mayo Clinic in the US – was collated. Results indicated a higher incidence of concurrent cancer in MOGAD patients compared to the general population. The underlying relationship between autoimmune diseases and cancer is emphasized, suggesting that chronic inflammation in autoimmune patients could potentially precipitate cancer. The study further examines if the myelin oligodendrocyte glycoprotein antibody, associated with MOGAD, is a direct product of cancer tissues or arises due to the environment within cancer patients. Preliminary sub-analysis reveals that 12% of MOGAD patients over 50 years have concurrent cancer. Hence, it’s advised that patients experiencing MOGAD onset post-50 should undergo cancer screening. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.